Yükleniyor... / Loading...
This study compares LGX818 (Encorafenib) plus Cetuximab with LGX818 plus BYL719 plus Cetuximab in patients with BRAF-mutant metastatic colorectal cancer. It included patients who had progressed after at least one prior standard regimen. It was a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+12
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Metastatic colorectal cancer * Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens * Life expectancy ≥ 3 months * ECOG performance status ≤ 2 Exclusion Criteria: * Symptomatic or untreated leptomeningeal disease * Symptomatic brain metastasis * Patients with clinically manifested diabetes * Acute or chronic pancreatitis * Clinically significant cardiac disease Other protocol-defined inclusion/exclusion criteria may apply.